Do risks outweigh benefits in thrombolysis for stroke?

BMJ (Online)

Volumn 347, Issue 7923, 2013, Pages

  Brown, Simon G A ^a,b   Macdonald, Stephen P J ^a,c   Hankey, Graeme J ^d,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Armadale Health Service   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

ARTICLE; BLOOD CLOT LYSIS; BRAIN DEATH; BRAIN FUNCTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; EMERGENCY PHYSICIAN; FOLLOW UP; HEALTH BELIEF; HEART INFARCTION; HUMAN; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

FIBRINOLYTIC AGENTS; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84883769537     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5215     Document Type: Article

References (36)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
3. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 1999;282:2019-26.
4. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-6. (Pubitemid 30198420)
5. Wardlaw JM, Murray V, Berge E, Del Zoppo G, Sandercock P, Lindley RL, Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-72.
6. Radecki RP. Skepticism about thrombolytics in stroke is not unreasonable. Nat Rev Neurol 2012;8:176.
7. Hoffman JR, Cooper RJ. How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST-3). Emerg Med Australas 2012;24:473-6.
8. Fatovich DM. Believing is seeing: Stroke thrombolysis remains unproven after the third international stroke trial (IST-3). Emerg Med Australas 2012;24:477-9.
9. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418-24. (Pubitemid 39328073)
10. Hoffman JR, Schriger DL. A graphic reanalysis of the NINDS Trial. Ann Emerg Med 2009;54:329-36, 336.e1-35.
11. Saver JL, Gornbein J, Starkman S. Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit. Stroke 2010;41:2381-90.
12. Shy BD. Implications of ECASS III error on emergency department treatment of ischemic stroke. J Emerg Med 2012 Nov 7 [Epub ahead of print].
13. Ferguson C. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: use of thrombolysis in acute ischaemic stroke. Emerg Med J 2010;27:245-8.
14. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352-63.
15. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke 2012;43:1691-4.
16. Radecki RP, Chathampally YG, Press GM. rt-PA and stroke: does IST-3 make it all clear or muddy the waters? Answers to the November 2012 journal club questions. Ann Emerg Med 2013;61:489-98.
17. IST-3 Collaborative Group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol 2013;8:768-76.
18. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-30.
19. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin scale: a systematic review. Stroke 2009;40:3393-5.
20. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity. 1. Clinical trials. Lancet 2001;357:373-80. (Pubitemid 32128549)
21. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82. (Pubitemid 46138121)
22. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74.
23. Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D, SITS Investigators. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the safe implementation of treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study. JAMA Neurol 2013;70:837-44.
24. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-12. (Pubitemid 40745072)
25. Shobha N, Buchan AM, Hill MD. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset-evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-8.
26. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med 2013;61:46-55.
27. Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian Stroke Center. Stroke 2013;44:2269-74.
28. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309:2480-8.
29. Strbian D, Meretoja A, Ahlhelm FJ, Pitkäniemi J, Lyrer P, Kaste M, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 2012;78:427-32.
30. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke 2012;43:1315-22.
31. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke prognostication using age and NIH stroke scale: SPAN-100. Neurology 2013;80:21-8.
32. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012;43:2904-9.
33. Sung SF, Chen SC, Lin HJ, Chen YW, Tseng MC, Chen CH. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2013;44:1561-6.
34. Rocco A, Heuschmann PU, Schellinger PD, Köhrmann M, Diedler J, Sykora M, et al. Glycosylated hemoglobin A1 predicts risk for symptomatic hemorrhage after thrombolysis for acute stroke. Stroke 2013;44:2134-8.
35. Mazya MV, Bovi P, Castillo J, Jatuzis D, Kobayashi A, Wahlgren N, et al. External validation of the SEDAN score for prediction of intracerebral hemorrhage in stroke thrombolysis. Stroke 2013;44:1595-600.
36. Stroke Thrombolysis Trialists' Collaborative Group. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. Int J Stroke 2013;8:278-83.